Table 4.
Predicted mean change in CD4 cell count at 6, 12 and 18 months among women with prevalent HIV infection using ART at enrollment, by contraceptive method.
| Predicted mean change in CD4 cell count, cells/mm3 (95% CI)a |
p Value (vs. nonhormonal) |
|||
|---|---|---|---|---|
| 6 months | 12 months | 18 months | ||
| Current contraceptive method (time-varying) | ||||
| COCs | 83.2 (23.0–143.4) | 106.0 (47.8–164.2) | 128.8 (68.9–188.7) | 0.1 |
| DMPA | 83.8 (8.5–159.2) | 106.6 (33.5–179.8) | 129.4 (55.7–203.2) | 0.3 |
| Nonhormonal | 45.9 (−10.3 to 102.0) | 68.7 (14.0–123.3) | 91.4 (34.5–148.4) | |
| Contraceptive method at enrollment | ||||
| COCs | 52.7 (−12.2 to 117.6) | 85.4 (24.2–146.7) | 118.2 (56.9–179.6) | 0.7 |
| DMPA | 80.3 (4.7–155.9) | 113.1 (41.5–184.7) | 145.8 (75.0–216.6) | 0.3 |
| Nonhormonal | 39.9 (−15.8 to 95.7) | 72.7 (20.1–125.4) | 105.5 (51.6–159.3) | |
ART, antiretroviral therapy.
a
Adjusted for CD4 cell count at enrollment, duration of ART use at enrollment (months), HAART regimen (yes/no) and time under observation in the study.